Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.

ABSTRACT:

Objective

To assess long-term (up to 2 years) efficacy, tolerability, and safety of erenumab for the prevention of episodic migraine (EM) in Japanese patients.

Background

Previously published results from the double-blind treatment phase (DBTP) of a phase 2 clinical study have demonstrated the efficacy and safety of erenumab in Japanese patients with EM.

Methods

Patients completing the 24-week placebo-controlled DBTP could continue into the 76-week open-label treatment phase (OLTP), receiving erenumab 70 mg or 140 mg subcutaneously once monthly. The initial dose in the OLTP was erenumab 70 mg monthly, which was later changed to 140 mg. After study completion, the following were assessed: change from baseline in monthly migraine days (MMD), change from baseline in mont

SUBMITTER: Sakai F 

PROVIDER: S-EPMC8251924 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature